Results 141 to 150 of about 28,272 (264)

Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study [PDF]

, 2016
Wenguang Wang, Yongfeng He, Yuan-li Chen, Fumei Zhao, Yanqiu Song, Hong Zhang, Yanhe Ma, Xin Guan, Wenya Zhang, Xiaolin Chen, Chao Liu, Hongliang Cong   +11 more
openalex   +1 more source

Butanolic Extract of Noni Inhibits Proliferation, Inflammation, and Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Cultured Smooth Muscle Cells [PDF]

, 2020
Takanori Matsui, Yuji Ishibashi, Ami Sotokawauchi, Fumiyuki Isami, Yumi Abe, Sho‐ichi Yamagishi   +5 more
openalex   +1 more source

Ramadan Intermittent Fasting Is Associated with Changes in Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Metabolically Healthy Obese Subjects [PDF]

, 2022
Hayder Hasan, Mohamed Madkour, Samir Awadallah, Mohamed Hassanein, Haitham Jahrami, MoezAlIslam E. Faris   +5 more
openalex   +1 more source

Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome

Archives of Rheumatology
Objectives: This study aimed to investigate the potential roles of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and apelin in the etiology of fibromyalgia syndrome (FS). Patients and methods: The retrospective study was conducted between May 2022 and February 2023.
Pihtili Taş, Nevsun, Aydogan Baykara, Rabia, Kamanli, Ayhan, Gürbüz, Ali, Cure, Erkan, Cumhur Cüre, Medine, Erdem, Mehmet, Tasar Yildirim, Tugce   +7 more
openaire   +2 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions

MedComm
Ischemic stroke remains a leading cause of global disability and death. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as potent lipid‐lowering agents with expanding therapeutic potential.
Jia Kuang, Lei Hao, Meibiao Zhang, Zhao Yang   +3 more
doaj   +1 more source

Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver

, 2020
Muhammad Shafiq, Timothy Walmann, Venkat Nutalapati, Cheryl Gibson, Yousaf Zafar   +4 more
openalex   +1 more source

Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor) [PDF]

, 2019
Ali Ben Djoudi Ouadda, Marie-Soleil Gauthier, Delia Susan‐Resiga, Emmanuelle Girard, Rachid Essalmani, Miles H. Black, Jadwiga Marcinkiewicz, Diane Forget, Josée Hamelin, Alexandra Evagelidis, Kévin Ly, Robert Day, Luc Galarneau, François Corbin, Benoit Coulombe, Artuela Çaku, Vincent S. Tagliabracci, Nabil G. Seidah   +17 more
openalex   +1 more source

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study [PDF]

, 2017
Joshua Choi, Amir Khan, Michael Jarmin, Naila Goldenberg, Charles J. Glueck, Ping Wang   +5 more
openalex   +1 more source

The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research. [PDF]

, 2013
Elguindy, A, Yacoub, MH
core   +1 more source

Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors- Are We Doing Better? A Systematic Review on Treatment Disparity [PDF]

, 2020
Chetana Singh, Danel J Valero, Javariya Nisar, J. I. Ramirez, Karisma K Kothari, Sasank Isola, Aleyda M San Hernandez, Domonick K Gordon   +7 more
openalex   +1 more source